A Comprehensive HLA-DR4 MHC Class II Tetramer Platform for the Detection and Functional Validation of Post-Translational Modification Neoantigens.

Henghui Li, Jingyao Li, Ying Wang, Hongyan Ma, Fen Tang, Liang Chen

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Henghui LiSchool of Medicine, Shanghai University, Shanghai 200444, China.ORCID 0009-0007-1457-379X

Jingyao LiSchool of Medicine, Shanghai University, Shanghai 200444, China.

Ying WangSchool of Medicine, Shanghai University, Shanghai 200444, China.

Hongyan MaSchool of Medicine, Shanghai University, Shanghai 200444, China.ORCID 0009-0000-6093-5340

Fen TangSchool of Medicine, Shanghai University, Shanghai 200444, China.

Liang ChenSchool of Medicine, Shanghai University, Shanghai 200444, China.

Funding

the Major Program of the National Natural Science Foundation of China No. 82293635the National Key Research and Development Program of China No. 2023YFC2306401the National Natural Science Foundation of China No. 82471823

6 · The paper itself

Abstract

Post-translational modification (PTM) neoantigens have emerged as key drivers of autoimmune inflammation. However, standardized protocols for MHC Class II tetramer preparation for the detection of such antigen-specific T cells remain limited, hindering the broader application of this important discovery. This study systematically engineered an HLA-DR4 (HLA-DRB1*04:02 and HLA-DRA*01:01) tetramer platform based on carboxyethyl-modified neoantigen ITGA2B peptide (ITG-CE), a PTM associated with autoimmune diseases (AUIDs) such as Ankylosing Spondylitis (AS). The platform provides a major histocompatibility complex (MHC) Class II tetramer associated with the PTM neoantigen and integrates modular protein construct, a controllable PTM peptide exchange strategy, and a specific T cell receptor (TCR) validation model. It can be employed to investigate PTM neoantigen presentation and CD4

Indexed as

HLA-DR4 AntigenProtein Processing, Post-TranslationalCD4-Positive T-LymphocytesHistocompatibility Antigens Class IIHumansReceptors, Antigen, T-CellSpondylitis, AnkylosingHistocompatibility Antigens Class IIHLA-DR4 AntigenReceptors, Antigen, T-Cellantigen-specific CD4+ T cellsautoimmune diseases (AUIDs)fluorescence polarization (FP)high-throughput screeningHLA-DR4major histocompatibility complex (MHC) class II tetramerpost-translational modification (PTM) neoantigensT-cell receptor (TCR) recognition

Identifiers

PMID42449937

DOI10.3390/ijms27135660

PMCPMC13361123

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.